Clinical Trial Update: Phase III Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer [Phase 3]

View source ↗

Summary

Phase III study evaluating DCVAC/PCa added to standard chemotherapy for metastatic castration-resistant prostate cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• DCVAC/PCa (dendritic cell vaccine DCVAC/PCa)

Snippet

Sponsor: SOTIO a.s. | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: COMPLETED | Results posted: 2021-04-06